Causal claim
Clinical Trial Readout Antisense OligonucleotideThe two move together: more cause, more effect. The map scores it at 1% confidence, weighed from 1 article.
GENERATION HD2 interim analysis of the tominersen ASO showed the 100mg dose more likely to yield clinical benefit and recommended the trial continue, supporting the huntingtin-lowering ASO approach
Nothing upstream on the map yet.